SCHEMBL1668685

SCHEMBL1668685

CC(=O)CC(C)NC(C)=O

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
MTNR1A P48039 12/20 0.41
MTNR1B P49286 12/20 0.41
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
NFKB1 P19838 1/20 0.38
PTGS2 P35354 1/20 0.38
THPO P40225 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ACACB O00763 3/20 0.38
CRAT P43155 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21462580 0.82 ALDH1A1 (0.48) ALDH1A1TDP1MTNR1AMTNR1BKDM4E
SCHEMBL21462579 0.82 ALDH1A1 (0.48) ALDH1A1TDP1MTNR1AMTNR1BKDM4E
SCHEMBL2766000 0.82 ALDH1A1 (0.45) ALDH1A1TDP1MTNR1AMTNR1BKDM4E
SCHEMBL795359 0.82 ALDH1A1 (0.45) ALDH1A1TDP1MTNR1AMTNR1BKDM4E
SCHEMBL18117431 0.82 ALDH1A1 (0.48) ALDH1A1TDP1MTNR1AMTNR1BKDM4E
SCHEMBL4378947 0.82 ALDH1A1 (0.45) ALDH1A1TDP1MTNR1AMTNR1BKDM4E
SCHEMBL20245188 0.80 MTNR1A (0.39) ALDH1A1TDP1MTNR1AMTNR1BKDM4E
SCHEMBL23445656 0.78 ALDH1A1 (0.56) ALDH1A1TDP1MAPTSMN1; SMN2ACACB
SCHEMBL20970384 0.78 CYP2C9 (0.45) ALDH1A1TDP1SMN1; SMN2ACACB
SCHEMBL18394981 0.78 MTNR1A (0.46) ALDH1A1MTNR1AMTNR1BKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3253752-B1 [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES INC (US) 2023-08-16 EP disclosed
EP-3082805-B1 SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME INST FOR DRUG DISCOVERY LLC (US) 2020-02-05 EP disclosed
US-20160297823-A1 SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME INSTITUTE FOR DRUG DISCOVERY, LLC 2016-10-13 US disclosed
WO-2015095701-A1 SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME THE INSTITUTE FOR DRUG DELIVERY (US) 2015-06-25 WO disclosed
WO-2012046062-A1 USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS SHIRE, LLC (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297823-A1 SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME CMA1, CHIA, AADAC ALDH1A1 1006/4885TDP1 1348/4885MTNR1A 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.